Vietnam Tuberculosis Therapeutics Market to Grow at 4.12% CAGR through 2029

Emergence of drug-resistant TB strains and government-led initiatives &  healthcare programs is expected to drive the Vietnam Tuberculosis Therapeutics Market growth in the forecast period, 2025-2029.

According to TechSci Research report, “Vietnam Tuberculosis Therapeutics Market –Industry Size, Share, Trends, Competition, Forecast & Opportunities, 2029F”, the Vietnam Tuberculosis Therapeutics Market stood at USD 25.48 Million in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 4.12% through 2029.  

The Vietnam Tuberculosis (TB) Therapeutics Market is characterized by a dynamic landscape shaped by various factors, including disease prevalence, healthcare infrastructure, government initiatives, and advancements in medical technology. TB remains a significant public health concern in Vietnam, with the country being among the 30 high TB burden countries globally. Despite concerted efforts to control the disease, TB continues to pose challenges to healthcare systems and communities across Vietnam.

One of the key features of the Vietnam TB Therapeutics Market is the high prevalence of TB within the population. Factors such as overcrowding, poverty, limited access to healthcare services, and the presence of risk factors like HIV/AIDS contribute to the ongoing transmission of TB within communities. As a result, Vietnam faces a considerable burden of both drug-susceptible TB and drug-resistant TB, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB).

In response to the TB burden, the Vietnamese government has implemented various TB control programs and initiatives aimed at prevention, diagnosis, and treatment. These efforts are supported by international organizations, non-governmental organizations (NGOs), and pharmaceutical companies, which provide funding, technical assistance, and resources to strengthen TB control efforts in Vietnam. The National TB Control Program (NTP) plays a central role in coordinating TB control activities, implementing standardized treatment protocols, and monitoring disease trends across the country.

In terms of therapeutics, the Vietnam TB Therapeutics Market primarily relies on first-line antibiotics for the treatment of drug-susceptible TB cases. Standard treatment regimens, such as the directly observed treatment, short-course (DOTS) strategy, are widely implemented to ensure patient adherence and treatment success. First-line antibiotics, including isoniazid, rifampicin, pyrazinamide, and ethambutol, are provided free of charge to TB patients through the NTP, ensuring equitable access to essential medications.

However, the emergence of drug-resistant TB strains poses challenges to TB treatment in Vietnam. MDR-TB and XDR-TB require specialized treatment regimens involving second-line and third-line antibiotics, which are more expensive, less effective, and associated with higher rates of adverse effects compared to first-line therapy. Managing drug-resistant TB cases requires specialized TB treatment centers equipped with laboratory facilities for drug susceptibility testing and monitoring patient response to treatment.

In recent years, advancements in medical technology have influenced the Vietnam TB Therapeutics Market, particularly in the realm of TB diagnostics. Rapid molecular diagnostic tests, such as GeneXpert MTB/RIF, have revolutionized TB diagnosis by enabling quick and accurate detection of TB and drug-resistant strains. These molecular tests offer significant advantages over traditional diagnostic methods, such as sputum microscopy, by providing faster results and detecting TB in HIV-positive individuals and pediatric patients more effectively.

Digital health technologies and telemedicine platforms have been leveraged to improve TB care delivery and patient management in Vietnam. Mobile health applications, remote monitoring tools, and electronic medical records facilitate communication between healthcare providers and TB patients, support treatment adherence, and track treatment outcomes. These digital solutions contribute to the optimization of TB care delivery, particularly in remote and underserved areas where access to healthcare services is limited.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Vietnam Tuberculosis Therapeutics Market”

The Vietnam Tuberculosis Therapeutics Market is segmented into disease type, therapy, regional distribution, and company.

Based on disease type, the emergence of drug-resistant strains of TB, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), contributes to the dominance of Active TB in the Vietnam Tuberculosis Therapeutics Market. Drug-resistant TB requires specialized treatment regimens involving second-line and third-line medications, which are more costly, complex, and associated with higher rates of adverse effects compared to standard TB therapy. As a result, the management of drug-resistant TB cases places a significant burden on healthcare systems and drives demand for specialized TB therapeutics tailored to the needs of these patients.

While Latent TB infection (LTBI) represents a significant reservoir of TB infection within the population, particularly among individuals with recent TB exposure or immunocompromised individuals, it does not typically manifest with clinical symptoms and does not require immediate therapeutic intervention in most cases. Instead, individuals with LTBI may be managed with preventive therapy, such as isoniazid or rifapentine, to reduce the risk of progression to active disease. While LTBI management is an essential component of TB control efforts, particularly in high-risk populations, the focus of the Vietnam Tuberculosis Therapeutics Market remains primarily on addressing the burden of Active TB through timely diagnosis, appropriate treatment, and comprehensive TB control strategies.

Based on region, North Vietnam emerges as the second dominant region in the Vietnam Tuberculosis (TB) Therapeutics Market due to several key factors influencing the TB burden and healthcare landscape in the region. North Vietnam encompasses major urban centers such as Hanoi, the capital city, and Hai Phong, which have relatively higher population densities compared to rural areas. This higher population density contributes to an increased prevalence of TB cases in the region, driving demand for TB diagnostics, treatments, and preventive measures.

North Vietnam benefits from better healthcare infrastructure and access to medical resources compared to remote and underserved areas in the country. Major cities in the region are equipped with well-established healthcare facilities, including hospitals, clinics, and specialized TB treatment centers, where patients can access quality TB care and therapeutics. North Vietnam is home to leading medical institutions, research centers, and academic institutions that foster innovation and collaboration in TB treatment and control efforts, further strengthening the region's position in the TB therapeutics market.

Major companies operating in Vietnam Tuberculosis Therapeutics Market are:

• Novartis Vietnam Company Limited
• Otsuka Pharmaceutical Vietnam JSC
• GSK Pharma Viet Nam Company Limited
• Nam Ha Pharmaceutical Joint Stock Company
• DHG Pharmaceutical Joint Stock Company
• Traphaco Joint Stock Company
• Ha Tay Pharmaceutical Joint Stock Company
• Vietnam Pharmaceutical Corporation
• Medipharco Pharmaceutical Joint Stock Company
• OPC Pharmaceutical Joint Stock Company

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The future of the Vietnam Tuberculosis Therapeutics Market holds promise amidst evolving healthcare dynamics and advancements in medical technology. With a concerted focus on TB control and elimination goals, coupled with ongoing investments in healthcare infrastructure and research, the market is poised for growth and innovation. Key drivers shaping the future of the market include the adoption of advanced diagnostic technologies, such as rapid molecular tests and digital health solutions, to improve TB detection and patient management. Efforts to address drug-resistant TB strains through the development of novel therapeutics and treatment regimens are expected to drive market expansion. Collaborative initiatives between government agencies, healthcare providers, and industry stakeholders will play a pivotal role in advancing TB control efforts and ensuring access to quality TB care for all populations. Overall, the future of the Vietnam Tuberculosis Therapeutics Market is characterized by a commitment to innovation, collaboration, and equitable access to healthcare, with the ultimate goal of achieving TB elimination in the country.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Vietnam Tuberculosis Therapeutics Market By Disease Type (Active Tuberculosis and Latent Tuberculosis), By Therapy (First Line Therapy and Second Line Therapy), By Region, Competition, Forecast and Opportunities, 2019-2029F”, has evaluated the future growth potential of Vietnam Tuberculosis Therapeutics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Vietnam Tuberculosis Therapeutics Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com